A tiny Israeli company has beaten some of the biggest medtechs in the world to the wireless charging of heart pumps.
Less than two years after setting up its BI X digital lab, Boehringer Ingelheim is ready to start clinical trials of a programme monitoring speech patterns to diagnose…
Intra-Cellular looks to shore up lumateperone, while Myovant wants to take on Abbvie on its own turf.
The notoriously secretive German pharma company Boehringer Ingelheim has made much of a new drive towards transparency, but there are still things it would rather keep to…
Johnson & Johnson’s Invokana has fallen behind SGLT2 rivals over amputation fears, but success in the Credence renal trial, profiled at the International Society of…
The group follows licensing deals with Dainippon and Roivant with a pivotal study win.
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
Savara Pharmaceuticals seeks to grab investor attention with upcoming pivotal data with an inhaled GM-CSF, Molgradex.
Investors had previously given Proteostasis the benefit of the doubt, but the company’s latest cystic fibrosis update leaves little hope to cling to.
Business development decisions have started the clock on a financial time bomb set to go off within the next three months.
Bristol-Myers Squibb’s $74bn bid for Celgene led to a huge quarter, but a drop in the deal count could give pause to those hoping for a bumper year.
Curevac’s decision to exit work on an mRNA approach to OTC deficiency follows a clinical hold on Translate Bio’s similar project, and raises broader concerns.